CervoMed (CRVO) vs Incannex Healthcare (IXHL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Incannex Healthcare (IXHL) has outperformed CervoMed (CRVO) over the past year, losing 80.3% versus a loss of 83.6%. Incannex Healthcare is the larger company by market cap ($23.3 million vs $22.1 million), about 1.1 times the size, while CervoMed is growing revenue faster (-58.9% vs -100.0%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVO | IXHL |
|---|---|---|
| Share price | $1.46 | $1.86 |
| Market cap | $22.09M | $23.34M |
| 1-day change | +9.77% | +6.90% |
| YTD return | -81.52% | -82.68% |
| 1-year return | -83.56% | -80.32% |
| 5-year return | -95.01% | — |
| EPS (TTM) | $-2.65 | $-1.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.01M | $0 |
| Revenue growth (YoY) | -58.86% | -100.00% |
| Net income (latest FY) | $-26.97M | $-19.30M |
| Operating margin | -706.22% | — |
| Net margin | -673.06% | — |
| 52-week high | $10.00 | $14.91 |
| 52-week low | $1.27 | $1.61 |
| Distance from 52-week high | -85.40% | -87.53% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +954.79% | +904.30% |
| Average volume | 489.10K | 91.61K |
| Shares outstanding | 15.13M | 12.55M |
| Employees | 15 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CervoMed grew revenue faster in its latest fiscal year (-58.86% vs -100.00%).
About CervoMed
CRVO stock →CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Incannex Healthcare
IXHL stock →Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
CRVO vs IXHL FAQ
Which is bigger, CervoMed or Incannex Healthcare?
Incannex Healthcare (IXHL) is larger, with a market capitalization of $23.34M compared with $22.09M for CervoMed (CRVO).
Which stock has performed better over the past year, CRVO or IXHL?
IXHL returned -80.32% over the past 12 months, compared with -83.56% for CRVO (price return, excluding dividends). Past performance does not predict future results.
Are CervoMed and Incannex Healthcare in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.